The Role of Placental Fas Ligand in Maintaining Immune Privilege at Maternal-Fetal Interfaces

Seminars in Reproductive Medicine

Volumn 17, Issue 1, 1999, Pages 39-44

  Guller, Seth ^a   LaChapelle, Linda ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

APOPTOSIS; CONFERENCE PAPER; CYTOLYSIS; EYE; HUMAN; IMMUNE RESPONSE; LARGE GRANULAR LYMPHOCYTE; MOTHER FETUS RELATIONSHIP; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLACENTA; PRIORITY JOURNAL; SYNCYTIOTROPHOBLAST; T LYMPHOCYTE; TESTIS; TROPHOBLAST;

APOPTOSIS; FAS LIGAND PROTEIN; FEMALE; FETUS; HUMANS; IMMUNE TOLERANCE; MEMBRANE GLYCOPROTEINS; PLACENTA; PREGNANCY; T-LYMPHOCYTES; TROPHOBLASTS;

EID: 0032975247     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1016210     Document Type: Article

References (53)

1. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-1456
2. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365
3. Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-563
4. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1995;75:1169-1178
5. Suda TS, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994;179: 873-879
6. Dhein J, Daniel ET, Trauth BC, Oehm A, Moller P. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992;149:3166-3173
7. Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G. The apoptosis endonuclease and its regulation. Semin Immunol 1992;4:389-397
8. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391:43-50
9. Sakahira H, Enari M, Shigekazu N. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96-99
10. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev 1995;9:2723-2735
11. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-817
12. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nature Med 1996;2:317-322
13. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733
14. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-736
15. Takashi S, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;12:2045-2050
16. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998;4:31-36
17. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand A, Fontana A, Lienard D, Cerottini J-C, Tschopp J. Melanoma cell expression of Fas APO-1/CD95 ligand: Implications for tumor escape. Science 1996;274:1363-1366
18. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariana SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 APO-1/Fas ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med 1996;2:1361-1366
19. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192
20. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke R. A role for CD95 in preventing graft rejection. Nature 1995;377:630-632
21. Saas P, Walker PR, Hahne M, Quiquerez A-L, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich P-Y. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-1178
22. Bobzien B, Yasunami Y, Majercik M, Lacy PE, Davie JM. Intratesticular transplants of islet xenografts rat to mouse. Diabetes 1983;32:213-216
23. Selawry HP, Whittington K. Extended allograft survival of islets grafted into intraabdominally placed testis. Diabetes 1984;33:405-406
24. Hunt JS, Orr HT. HLA and maternal-fetal recognition. FASEB J 1992;6:2344-2348
25. Wood GW. Is restricted antigen presentation the explanation for fetal allograft survival? Immunol Today 1994;15: 15-18
26. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-494
27. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-223
28. Hunt JS, Hsi BL. Evasive strategies of trophoblast cells: Selective expression of membrane antigens. Am J Repod Immunol 1990;23:57-63
29. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997;94:11520-11525
30. Graham CH, Lysiak JJ, McCrae KR, Lala PK. Localization of transforming growth factor-βat the human fetal-maternal interface: Role in trophoblast growth and differentiation. Biol Reprod 1992;46:561-572
31. Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin-10. J Exp Med 1996;184:539-548
32. Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 1995;7: 175-184
33. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992;148:277-284
34. O'Connell J, O'Sullivan GC, Collins JK, Shanahan FS. The Fas counterattack: Fas-mediated killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-1082
35. Payne SC, Smith SC, Davidge ST, Baker PN, Guilbert LJ. The death receptor Fas/Apo-1/CD95 expressed by placental cytotrophoblasts does not mediate apoptosis. Biol Reprod 1999;60:1144-1150
36. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Guller S. Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival. J Clin Endocrinol Metab 1996;81:3119-3122
37. Bamberger A-M, Schulte HM, Thuneke I, Erdmann I, Bamberger CM, Asa SL. Expression of the apoptosis-inducing Fas ligand FasL in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab 1997; 82:3173-3175
38. Mor G, Gutierrez S, Eliza M, Kahyaoglu F, Arici A. Fas-Fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. AJRI 1998;40:89-94
39. Uckan D, Steele A, Cherry, Wang B-Y, Chamizo W, Koutsonikolis A, Gilbert-Barness E, Good RA. Trophoblasts express Fas ligand: A proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod 1997;3:655-662
40. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in the mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and conceptus. J Immunol 1997;158:4122-4128
41. King A, Burrows T, Loke YW. Human uterine natural killer cells. Nat Immun 1996;15:41-52
42. Pace D, Longfellow M, Bulmer J. Characterization of intraepithelial lymphocytes in human endometrium. J Reprod Fertil 1991;91:165-174
43. King A, Loke YW. Human trophoblast and JEG choriocarcinoma cells are sensitive to lysis by IL-2-stimulated decidual NK cells. Cell Immunol 1990;129:435-448
44. King A, Loke YW, Effect of IFN-γand IFN-αon killing of human trophoblast by decidual LAK cells. J Reprod Immunol 1993;23:51-62
45. King A, Wooding P, Gardner L, Loke YW. Expression of perforin, granzyme A and TIA-1 by human uterine CD56+ NK cells implies they are activated and capable of effector functions. Hum Reprod 1993;8:2061-2067
46. Croy BA, Guimond MJ, Luross J, Hahnel A, Wang B, van den Heuvel M. Uterine natural killer cells do not require interleukin-2 for their differentiation or maturation. Am J Reprod Immunol 1997;37:463-470
47. Ye W, Zheng LM, Young JD, Liu CC. The involvement of interleukin IL-15 in regulating the differentiation of granulated metrial gland cells in mouse pregnant uterus. J Exp Med 1996;184:2405-2410
48. Allen MP, Nilsen-Hamilton M. Granzymes D, E, F, and G are regulated through pregnancy and by IL-2 and IL-15 in granulated metrial gland cells. J Immunol 1998;161:2772-2779
49. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and its role in chronic inflammatory diseases. Inflamm Res 1998;47:285-289
50. lRunic R, Lockwood CJ, LaChapelle L, DiPasquale B, Demopoulus RI, Kumar A, Guller S. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab 1998;93:660-666
51. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281: 1191-1193
52. Bonney EA, Matzinger P. The maternal immune system's interaction with circulating fetal cells. J Immunol 1997; 158:40-47
53. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 1995;270:630-633